Substantia Nigra Pars Compacta Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The substantia nigra pars compacta (SNc) contains the majority of dopaminergic neurons in the midbrain and is the primary site of neurodegeneration in Parkinson's disease. These neurons project to the striatum forming the nigrostriatal pathway, critical for motor control.
| Attribute | Value |
|---|---|
| Cell Type | Substantia Nigra Pars Compacta Dopaminergic Neurons |
| Location | Midbrain, Substantia Nigra |
| Lineage | Dopaminergic Neurons (A9) |
| Marker Genes | TH, DAT (SLC6A3), AADC (DDC), PITX3, NURR1, ALDH1A1 |
| Brain Regions | Striatum, Basal Ganglia |
SNc dopaminergic neurons have distinctive features:
Key markers in SNc dopaminergic neurons:
| Marker | Type | Function |
|---|---|---|
| TH | Enzyme | Tyrosine hydroxylase - rate-limiting for dopamine synthesis |
| DDC | Enzyme | Dopa decarboxylase - converts L-DOPA to dopamine |
| SLC6A3 | Transporter | Dopamine transporter (DAT) - reuptake |
| PITX3 | TF | Transcription factor - development and survival |
| NR4A2/NURR1 | TF | Nuclear receptor - dopaminergic differentiation |
| ALDH1A1 | Enzyme | Aldehyde dehydrogenase - dopamine metabolism |
| CALB1 | Calcium Binding | Calbindin - neuroprotection marker |
The study of Substantia Nigra Pars Compacta Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Fearnley, J. M., & Lees, A. J. (1991). Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain, 114(Pt 5), 2283-2301.
[2] Surmeier, D. J., et al. (2017). Calcium and Parkinson's disease. Biochemical and Biophysical Research Communications, 483(4), 1013-1018.
[3] Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912.
[4] Sulzer, D., & Surmeier, D. J. (2013). Neuronal vulnerability, pathogenesis, and Parkinson's disease. Movement Disorders, 28(6), 715-724.
[5] Damier, P., et al. (1999). The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122(Pt 8), 1437-1448.
[6] Björklund, A., & Dunnett, S. B. (2007). Dopamine neuron systems in the brain: Emerging facts and insights. Neuropsychopharmacology, 32(1), 1-10.
[7] Jankovic, J., & Tolosa, E. (2007). Parkinson's Disease and Movement Disorders. Lippincott Williams & Wilkins.
[8] Poewe, W., et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.